Expansion Into Advanced Therapies Will Diversify Revenue Streams And Strengthen Market Position

AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Published
14 Mar 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
€24.50
47.2% undervalued intrinsic discount
08 Aug
€12.94
Loading
1Y
-28.5%
7D
2.4%

Author's Valuation

€24.5

47.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 3.99%

Shared on24 Apr 25
Fair value Decreased 4.42%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on17 Apr 25

AnalystConsensusTarget has increased profit margin from 1.7% to 1.9% and decreased future PE multiple from 25.6x to 22.5x.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.14%

AnalystConsensusTarget has decreased profit margin from 2.3% to 1.7%, increased future PE multiple from 16.4x to 25.6x and increased shares outstanding growth rate from 0.0% to 0.1%.

Shared on26 Mar 25
Fair value Decreased 4.98%

AnalystConsensusTarget has decreased revenue growth from 4.6% to 3.6%, decreased profit margin from 2.7% to 2.3% and decreased shares outstanding growth rate from 0.1% to 0.0%.

Shared on19 Mar 25
Fair value Decreased 5.64%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.